The BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2020.

**BIO Investor Forum features include:**
- Public and venture-stage company presentations.
- Expert-led workshops on the latest market and investment opportunities with emphasis on drug and technology development.
- BIO One-on-One Partnering™ meetings.
- Premier opportunity to network with industry executives and investors focused exclusively on life sciences.

**Audience Demographics**

**TARGET AUDIENCE**

Private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences.

Companies by Type

- Biopharma: 42%
- Investor: 25%
- Other: 33%

Investors by Investor Type

- Biopharma: 62%
- Investor: 9%
- Other: 7%
- Royalty/Debt Financing (PM, Buy-Side Research): 6%
- Angel Investing: 5%
- Venture Philanthropy: 4%
- Venture Capital/Corporate VC: 3%
- Other: 2%
- Family Office: 2%
- Other: 2%
- Endowment/Foundation: 1%
- Sell-Side Research: 1%
- Buy-Side Research: 1%
- Endowment/Foundation: 1%
- Other: 1%

**Attendees**

1,000+

**Partnering Meetings Scheduled**

3,000+

**Presenting Companies**

170

“Like being at JPM without the crowds.”

Like being at JPM without the crowds.
Why Companies Attend

- **Meet** one-on-one with new and current investors, analysts, and partnering companies.
- **Get the pulse** on the latest life sciences investment trends from sophisticated investment and company executives.
- **Showcase** your company story in presentations to qualified investors.
- **Network** with peers, investors and potential partners.

Why Investors Attend

- **Hear from and meet** with executives at the top life sciences growth companies.
- **Evaluate** fresh investment opportunities including compatible, complementary and competitive companies.
- **Benefit** from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.
- **Get a ‘big picture’ overview** of the industry and the issues affecting product innovation, capitalization, and commercialization.

2018 BIO Investor Forum

**TOP THERAPEUTIC AREAS FOR SCHEDULED MEETINGS**

"The investors were great. I don’t know what similar access I’ll have to such a collection again."

"Excellent forum for meeting investors or alliance partners for biotech deals."
Leaders from six companies at the forefront of microbiome innovation assembled to discuss the latest developments in microbiome-based approaches to improve patient outcomes, including microbiome transplants, bioengineered probiotics, next-generation antibiotics, and microbiome-based drug discovery platforms during Wednesday morning’s panel, “Using Microbiome-Based Therapies to Improve Patient Outcomes”.

BIO’s CEO Jim Greenwood reflected on the past 25 years of BIO history and highlighted where the industry is headed before Wednesday’s Fireside Chat featuring Ed Hurwitz, JD, of MPM Capital and Susanne Mulligan of BMO Capital Markets.

During “View from the Board: Responding to an Acquisition Offer”, panelists were presented with a real-world developing scenario involving an acquisition offer. They responded with practical advice, outlined the sometimes complicated implications of certain situations, and discussed how they would react.

Day 1 of the event wrapped up with a networking reception for all attendees on the top floor of the Tower Building at the Westin St. Francis.

The panel, “‘Digiticeuticals’ as a New Class of FDA-Approved Therapeutics: Investment & Partnering Opportunities”, explored the expansion of this biotech that enables fundamental changes in managing interactions with patients to understand and treat disease.

Thursday’s Plenary Luncheon Fireside Chat featured two industry leaders: Rowan Chapman, PhD, head of Johnson & Johnson Innovation, California, and moderator Deepa Pakianathan, PhD, managing partner of Delphi Ventures. Their diverse experiences provided unique insights into how big and small companies approach partnering and investing—and the different points of view that they bring to decision making.

3,010 BIO One-on-One Partnering™ meetings took place during the 2-day event!

The two-day event hosted over 1,000 Attendees.

3,010 BIO One-on-One Partnering™ meetings took place during the 2-day event!

BIO’s CEO Jim Greenwood reflected on the past 25 years of BIO history and highlighted where the industry is headed before Wednesday’s Fireside Chat featuring Ed Hurwitz, JD, of MPM Capital and Susanne Mulligan of BMO Capital Markets.

During “View from the Board: Responding to an Acquisition Offer”, panelists were presented with a real-world developing scenario involving an acquisition offer. They responded with practical advice, outlined the sometimes complicated implications of certain situations, and discussed how they would react.

Day 1 of the event wrapped up with a networking reception for all attendees on the top floor of the Tower Building at the Westin St. Francis.

The panel, “‘Digiticeuticals’ as a New Class of FDA-Approved Therapeutics: Investment & Partnering Opportunities”, explored the expansion of this biotech that enables fundamental changes in managing interactions with patients to understand and treat disease.

Thursday’s Plenary Luncheon Fireside Chat featured two industry leaders: Rowan Chapman, PhD, head of Johnson & Johnson Innovation, California, and moderator Deepa Pakianathan, PhD, managing partner of Delphi Ventures. Their diverse experiences provided unique insights into how big and small companies approach partnering and investing—and the different points of view that they bring to decision making.

3,010 BIO One-on-One Partnering™ meetings took place during the 2-day event!

BIO’s CEO Jim Greenwood reflected on the past 25 years of BIO history and highlighted where the industry is headed before Wednesday’s Fireside Chat featuring Ed Hurwitz, JD, of MPM Capital and Susanne Mulligan of BMO Capital Markets.

During “View from the Board: Responding to an Acquisition Offer”, panelists were presented with a real-world developing scenario involving an acquisition offer. They responded with practical advice, outlined the sometimes complicated implications of certain situations, and discussed how they would react.

Day 1 of the event wrapped up with a networking reception for all attendees on the top floor of the Tower Building at the Westin St. Francis.

The panel, “‘Digiticeuticals’ as a New Class of FDA-Approved Therapeutics: Investment & Partnering Opportunities”, explored the expansion of this biotech that enables fundamental changes in managing interactions with patients to understand and treat disease.